Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464165 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2TACR3SLC6A3MEN1 | |
| SCHEMBL13733972 | 0.87 | SLC6A4 (0.46) | SLC6A4SLC6A2TACR3SLC6A3 | |
| SCHEMBL13735130 | 0.87 | SLC6A4 (0.46) | SLC6A4SLC6A2TACR3SLC6A3 | |
| SCHEMBL15464200 | 0.87 | SLC6A4 (0.46) | SLC6A4SLC6A2TACR3SLC6A3 | |
| Fumaric Acid SCHEMBL13734609 | 0.83 | TACR3 (0.44) | SLC6A4SLC6A2TACR3SLC6A3 | |
| Fumaric Acid SCHEMBL13734608 | 0.83 | TACR3 (0.44) | SLC6A4SLC6A2TACR3SLC6A3 | |
| SCHEMBL3742127 | 0.83 | SLC6A3 (0.46) | SLC6A4SLC6A2TACR3SLC6A3MEN1 | |
| SCHEMBL2473703 | 0.82 | SLC6A3 (0.45) | SLC6A4TACR3SLC6A3MEN1NPC1 | |
| SCHEMBL13734928 | 0.81 | SLC6A4 (0.36) | SLC6A4SLC6A2TACR3SLC6A3 | |
| SCHEMBL13735536 | 0.81 | SLC6A2 (0.48) | SLC6A4SLC6A2TACR3SLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699539-A2 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | Emory University (US) | 2014-02-26 | — | — | EP | claimed |
| US-20140045936-A1 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2014-02-13 | — | — | US | claimed |
| WO-2012145234-A2 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-10-26 | — | — | WO | claimed |
| US-10207984-B2 | Cyclopropyl derivatives and methods of use | EMORY UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20160244403-A1 | Cyclopropyl Derivatives and Methods of Use | UNIV EMORY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20140045936-A1 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244403-A1 | Cyclopropyl Derivatives and Methods of Use | CNR2, FKBP8, FKBP5 | SLC6A4 102/4885SLC6A2 472/4885TACR3 2372/4885 |
| US-10207984-B2 | Cyclopropyl derivatives and methods of use | CNR2, FKBP8, FKBP5 | SLC6A4 102/4885SLC6A2 472/4885TACR3 2372/4885 |
| US-20140045936-A1 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | CNR2, FKBP8, FKBP5 | SLC6A4 102/4885SLC6A2 472/4885TACR3 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.